x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

CME/CE

Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD"s CME activities. Our topics span cardiology, diabetes, oncology, women"s health and more. And our CME library is continuously growing, every quarter.

science & medicine medicine

All Episodes

00:00:00

Updates in Major Depressive Disorder with Insomnia

CME/CE ·

2025/11/07

Faculty: Michael E. Thase, MD Faculty: Andrew Krystal, MD Approximately 75% to 90% of patients with depression experience insomnia. This means that a very significant portion of individuals struggling with depression also have difficulty sleeping. Join Drs. Michael Thase and Andrew Krystal for this expert discussion to learn about the most recent data presented at the Psych Congress 2025 in San Diego on emerging therapies, such as the selective OX2R antagonists to treat major

en

00:00:00

APOL1 Screening and Early Detection: Patient and...

CME/CE ·

2025/10/21

Faculty: Kirk Campbell, MD Guest: Joshua Albright Guest: Titilayo Ilori, MBBS Host: Kirk Campbell, University of PennsylvaniaGuests: Joshua Albright, Kidney Health Advocate & Titilayo Ilori, Boston UniversityJoin our host Dr. Kirk Campbell (University of Pennsylvania) as he speaks with Dr. Titilayo Ilori (Boston University) and patient advocate Joshua Albright about APOL1 screening and early detection.This episode addresses the low public awareness of APOL1-mediated kidney

en

00:00:00

Burden and pathophysiology of APOL1 kidney disease

CME/CE ·

2025/10/21

Faculty: Kirk Campbell, MD Faculty: Bessie Young, MPH, MD Welcome to KDIGO Conversations in Nephrology: Burden and Pathophysiology of APOL1 Kidney Disease! Join our host Dr. Kirk Campbell (University of Pennsylvania) as he speaks with Dr. Bessie Young (University of Washington) about the discovery, impact, and future of APOL1 kidney disease. This episode explores the significant burden of kidney disease driven by APOL1 gene variants in individuals with African ancestry. You’ll

en

00:00:00

PI3K Pathway Inhibition in HR+/HER2- mBC: Mechanistic...

CME/CE ·

2025/10/07

Faculty: Komal Jhaveri, MD, FACP Faculty: Kevin Kalinsky MD, MS The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately

en

00:00:00

Comprehensive Biomarker Testing in mBC Informs...

CME/CE ·

2025/10/07

Faculty: Komal Jhaveri, MD, FACP Faculty: Kevin Kalinsky MD, MS The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately

en

00:00:00

Triple Threat: Key Data on Simultaneous Estrogen,...

CME/CE ·

2025/10/07

Faculty: Komal Jhaveri, MD, FACP Faculty: Kevin Kalinsky MD, MS The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately

en

00:00:00

Understanding Endocrine Resistance in HR+/HER2- mBC

CME/CE ·

2025/10/07

Faculty: Kevin Kalinsky MD, MS The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately preventing tumor formation and

en

00:00:00

The Future of PI3K Inhibition in HR+/HER2- Breast Cancer

CME/CE ·

2025/10/07

Faculty: Komal Jhaveri, MD, FACP Faculty: Kevin Kalinsky MD, MS The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately

en

00:00:00

Double Take: Pivotal Data Evaluating PI3K...

CME/CE ·

2025/10/07

Faculty: Komal Jhaveri, MD, FACP Faculty: Kevin Kalinsky MD, MS The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately

en

00:00:00

PI3K Pathway Inhibitors: Safety and Tolerability...

CME/CE ·

2025/10/07

Faculty: Komal Jhaveri, MD, FACP Faculty: Kevin Kalinsky MD, MS The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately

en

00:00:00

Case in Point: Applying PI3K Combinations in Early...

CME/CE ·

2025/10/07

Faculty: Komal Jhaveri, MD, FACP Faculty: Kevin Kalinsky MD, MS The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately

en

00:00:00

Monitoring FSGS: Traditional and Novel Biomarkers

CME/CE ·

2025/09/19

Faculty: Meghan Sise, MD Faculty: Vladimir Tesar Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals for many patients. But the current use of patient-reported outcomes (PROs), as well as emerging treatments on the horizon, may prove to be valuable tools in shaping the future of FSGS care.

en

00:00:00

FSGS: Interpretation of Proteinuria Reduction Thresholds

CME/CE ·

2025/09/19

Faculty: Vladimir Tesar Faculty: Meghan Sise, MD Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals for many patients. But the current use of patient-reported outcomes (PROs), as well as emerging treatments on the horizon, may prove to be valuable tools in shaping the future of FSGS care.

en

00:00:00

Current FSGS Treatment Landscape: More Questions Than...

CME/CE ·

2025/09/19

Faculty: Vladimir Tesar Faculty: Meghan Sise, MD Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals for many patients. But the current use of patient-reported outcomes (PROs), as well as emerging treatments on the horizon, may prove to be valuable tools in shaping the future of FSGS care.

en

00:00:00

Treatment Considerations for Pediatric Patients With...

CME/CE ·

2025/09/19

Faculty: Kenneth Lieberman, MD Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals for many patients. But the current use of patient-reported outcomes (PROs), as well as emerging treatments on the horizon, may prove to be valuable tools in shaping the future of FSGS care.

en

00:00:00

FSGS: When Solutions Fall Short

CME/CE ·

2025/09/19

Faculty: Meghan Sise, MD Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals for many patients. But the current use of patient-reported outcomes (PROs), as well as emerging treatments on the horizon, may prove to be valuable tools in shaping the future of FSGS care.

en

00:00:00

DEARA Versus SOC in FSGS Management: Clinical Trial...

CME/CE ·

2025/09/19

Faculty: Vladimir Tesar Faculty: Meghan Sise, MD Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals for many patients. But the current use of patient-reported outcomes (PROs), as well as emerging treatments on the horizon, may prove to be valuable tools in shaping the future of FSGS care.

en

00:00:00

Emerging Therapies in Managing Adult and Pediatric...

CME/CE ·

2025/09/19

Faculty: Vladimir Tesar Faculty: Meghan Sise, MD Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals for many patients. But the current use of patient-reported outcomes (PROs), as well as emerging treatments on the horizon, may prove to be valuable tools in shaping the future of FSGS care.

en

00:00:00

Integrating the Patient Voice in FSGS Management

CME/CE ·

2025/09/19

Faculty: Meghan Sise, MD Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals for many patients. But the current use of patient-reported outcomes (PROs), as well as emerging treatments on the horizon, may prove to be valuable tools in shaping the future of FSGS care.

en

00:00:00

Future Directions in FSGS Care

CME/CE ·

2025/09/19

Faculty: Kenneth Lieberman, MD Faculty: Vladimir Tesar Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals for many patients. But the current use of patient-reported outcomes (PROs), as well as emerging treatments on the horizon, may prove to be valuable tools in shaping the future of FSGS

en

267 results

Similar Podcasts

科学史评话最新专辑

科学史评话

Hablando con Científicos - Cienciaes.com

cienciaes.com

天方烨谈

基因频道

The Permaculture Podcast

Scott Mann

汪诘：科学有故事（主打）

科学有故事